Surfing the MASH Tsunami

Send us Fan Mail

Surfing the NASH Tsunami celebrates its 3rd anniversary since the debut episode posted on April 15, 2020. The Big Band of Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green get together to reflect on key moments from the podcast’s history as well as predict milestones that will make the highlights in a 6th anniversary special three years into the future.

This conversation focuses more on the trajectory of liver science than on the podcast itself. Starting with Stephen, Roger asks what has played out in the last three years that would and would not have been expected. Stephen articulates a most cogent response to recap critical evolutions witnessed by the field over the past 36 months. Number one on this list is the “advancement of our understanding of the noninvasive technologies and the diagnostic algorithms that have reached alignment by multiple different societies.” This point leads to discussion of how he has come to think of the role of biopsy and comments around the development of cohesive guidance documents for diagnosing patients. An invaluable takeaway: “There is a roadmap to get people to therapy.” From here Stephen continues to elucidate on what’s happening in the biomarker field before expressing interest in what’s emerging from the developments of AI-assisted digital pathology. Lastly, Stephen underscores that a wealth of information is contributing to new targets for drug development trials. As the session winds down, Jörn highlights his excitement for both the acceleration of opportunities generated by drug companies and the ongoing strength in the role of academia.

If you enjoy the special, have questions or interest around Fatty Liver disease, please let us know your ideas by writing to [email protected] and leaving a review wherever you download the discourse.

Stay Safe and Surf On!

Send us Fan Mail

Surfing the NASH Tsunami celebrates its 3rd anniversary since the debut episode posted on April 15, 2020. The Big Band of Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green get together to reflect on key moments from the podcast’s history as well as predict milestones that will make the highlights in a 6th anniversary special three years into the future.

This conversation features some amusing throwback clips to the first-time appearances of Stephen, Louise and Jörn on the podcast. Stephen notes that since his debut episode, more and more positive data continues to emerge from the field. Louise recalls her debut as rather impromptu and enticing from a nursing perspective. Jörn talks about how he discovered the podcast and eventually appeared as a guest. The group goes on to discuss a particularly exhilarating episode which demonstrated the “strongest emotion yet” on the podcast. Tune in to hear the full story.

If you enjoy the special, have questions or interest around Fatty Liver disease, please let us know your ideas by writing to [email protected] and leaving a review wherever you download the discourse.

Stay Safe and Surf On!

Send us Fan Mail

Surfing the NASH Tsunami celebrates its 3rd anniversary since the debut episode posted on April 15, 2020. The Big Band of Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green get together to reflect on key moments from the podcast’s history as well as predict milestones that will make the highlights in a 6th anniversary special three years into the future.

This initial conversation begins by catching up with Stephen as he provides a crash-course on the myriad of activities that have kept him busy since last appearing on the podcast. He talks about working on improving the ways in which we enroll for clinical trials and addressing screen fail rates. Stephen goes on to describe “focusing diligently on efforts with digital pathology to bridge the gap between ordinal path reading and noninvasive testing reading.” He notes the ability of the various consortia in driving the paradigm forward on diagnosis, monitoring, response to therapy and predicting long term outcomes using noninvasive testing strategy.

Later on, Roger cues a throwback to the original Surfing NASH introduction which kicked off some of the earlier episodes. It’s evident that the program has come a long way not only in its production, but also in discourse as the field progresses with time. This leads the group to reminisce on some of the bolder moments in the podcast’s history.

If you enjoy the special, have questions or interest around Fatty Liver disease, please let us know your ideas by writing to [email protected] and leaving a review wherever you download the discourse.

Stay Safe and Surf On!

Send us Fan Mail

This week, Surfing the NASH Tsunami celebrates its 3rd anniversary since the debut episode posted on April 15, 2020. We are offering a jam-packed special featuring individual interviews with guests Amy Articolo of Novo Nordisk, Donna Cryer of the Global Liver Institute, and Frédéric Cren of Inventiva Pharma.

In this final interview, Frédéric, Louise Campbell and Roger Green exchange ideas around, among other topics, the history and development of Inventiva’s lead product candidate, PPAR agonist lanifibranor.

If you enjoy the special, have questions or interest around Fatty Liver disease, please let us know your ideas by writing to [email protected] and leaving a review wherever you download the discourse.

Stay Safe and Surf On!

Send us Fan Mail

This week, Surfing the NASH Tsunami celebrates its 3rd anniversary since the debut episode posted on April 15, 2020. We are offering a jam-packed special featuring individual interviews with guests Amy Articolo of Novo Nordisk, Donna Cryer of the Global Liver Institute, and Frédéric Cren of Inventiva Pharma.

In this conversation, Louise Campbell and Roger Green sit down with Donna to reflect on the last three years in NASH-ville and predict what the next three will look like. Among other notes, Donna describes the ongoing process of activating all within the NASH community to fight fatty liver disease. 

If you enjoy the special, have questions or interest around Fatty Liver disease, please let us know your ideas by writing to [email protected] and leaving a review wherever you download the discourse.

Stay Safe and Surf On!

Send us Fan Mail

This week, Surfing the NASH Tsunami celebrates its 3rd anniversary since the debut episode posted on April 15, 2020. We are offering a jam-packed special featuring individual interviews with guests Amy Articolo of Novo Nordisk, Donna Cryer of the Global Liver Institute, and Frédéric Cren of Inventiva Pharma.

In this conversation with Amy, Louise Campbell and Roger Green, the group reflects on the last three years in NASH-ville and predict what the next three will look like. Amy discusses ‘ah-ha’ moments, the power of collaboration, clinical care pathways and the therapeutic trajectory of fighting fatty liver disease. 

If you enjoy the special, have questions or interest around Fatty Liver disease, please let us know your ideas by writing to [email protected] and leaving a review wherever you download the discourse.

Stay Safe and Surf On!

Send us Fan Mail

This week, Surfing the NASH Tsunami celebrates its 3rd anniversary since the debut episode posted on April 15, 2020. We are offering a jam-packed special featuring commentary from the original Big Band of Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. The second leg of the special features individual interviews with guests Amy Articolo of Novo Nordisk, Donna Cryer of the Global Liver Institute, and Frédéric Cren of Inventiva Pharma.

These conversations reflect on the last three years in NASH-ville and predict what the next three will look like. Plus, listeners also can enjoy throwbacks to key moments in the podcast's history of when we met our beloved Surfers. 

0:00 Introduction to the Surfing NASH 3rd Anniversary Special
2:31 Co-Surfer Roundtable: Revisiting Highlights from 3 Years on the Podcast
2:48 Catching Up with Stephen Harrison
8:28 How It All Started
13:24 Throwback to Meeting Stephen Harrison
16:02 Throwback to Meeting Louise Campbell
18:34 Throwback to Meeting Jörn Schattenberg
21:32 Strongest Emotion Recorded on the Podcast
22:39 Throwback to Meeting Donna Cryer
24:42 The Expected vs the Unexpected Over 3 Years in the Fatty Liver Space
39:45 The Straightjacket of Biopsy
45:30 Canary in the Coal Mine
48:06 Predictions for the Surfing NASH 6th Anniversary
58:35 Interview with Amy Articolo of Novo Nordisk
1:12:43 Interview with Donna Cryer of the Global Liver Institute
1:28:11 Interview with Frédéric Cren of Inventiva Pharma
1:40:30 Business Report

If you enjoy the special, have questions or interest around Fatty Liver disease, please let us know your ideas by writing to [email protected] and leaving a review wherever you download the discourse.

Stay Safe and Surf On!

Send us Fan Mail

Thursday, June 9, 2022 was the 5th International NASH Day (#NASHDay). Global Liver Institute, the largest liver patient advocacy organization in the world, and 200 partner organizations held a day of education, awareness and motivation for Fatty Liver stakeholders across the globe.

For its wrap-up panel, GLI invited the SurfingNASH co-host team to sit with Jeff McIntyre and review some of the day’s major themes as well as major developments since the last International NASH Day. Like a typical SurfingNASH episode, there were equal parts big-picture thinking, references to recent events, and laughs. Listen for a fast-paced discussion of big-picture items, most of which are different from the Episode 28 discussion.

Send us Fan Mail

As International #NASHDay 2023 approaches on June 8th, Surfing NASH dedicates a session to explore what makes this year’s occasion incredibly important for patient advocacy and what we all can consider in preparation. Founder, President and Chief Executive Officer of the Global Liver Institute (GLI), Donna Cryer, shares her anticipations alongside Pamela Danagher (Terns Pharmaceuticals) and co-hosts Jörn Schattenberg and Roger Green.

In this final session, Donna has departed and the remaining panelists propose ways by which to we can “step up” for this year’s #NASHDay. Jörn notes the benefit of early planning to prepare promotion and engagement within his own clinic and the various professional societies. Roger suggests obesity to be an intertwined area of focus important to include in #NASHDay activities. From an industry perspective, Pam is interested in working with the assistance and collaboration of regulatory authorities to create drug development pathways that are simpler, faster, less invasive and minimize the need for any unnecessary biopsies. Roger states that the way we envision the future is limited by biopsy in terms of the definition of what efficacy is and how to conduct clinical trials. For him, a big step up for all is to adopt a bold and expansive view of how the world is going to change and to anticipate with proactivity.

If you enjoy the episode, have questions or interest around its contents and Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Further, if you have questions or interest around participating in #NASHDay 2023, please let us know your ideas by writing to [email protected].

Stay Safe and Surf On!

Send us Fan Mail

As International #NASHDay 2023 approaches on June 8th, Surfing NASH dedicates a session to explore what makes this year’s occasion incredibly important for patient advocacy and what we all can consider in preparation. Founder, President and Chief Executive Officer of the Global Liver Institute (GLI), Donna Cryer, shares her anticipations alongside Pamela Danagher (Terns Pharmaceuticals) and co-hosts Jörn Schattenberg and Roger Green.

The group considers what activating awareness looks like in different community settings. Donna notes the opportunity for larger companies to be involved in educating employees on liver health. To assist in landing these opportunities, GLI is creating toolkits and presentations to educate and engage employees. Jörn adds that simple engagement with family members is also a critical opportunity for advocacy as we know there are higher rates of incidence in fatty liver disease for those sharing common genetics, diets and environments. Pamela raises the role of noninvasive technologies in screening/diagnosing patients and developing robust trial entry pathways. This prompts Donna to express her interest in facilitating mobile FibroScan clinics. Roger points out that should there be a NASH drug approval, more attention and energy will be dedicated to educating and treating fatty liver. As ideas continue to flow, it is eventually noted that fatty liver disease could benefit from having a celebrity patient advocate. One such celebrity who is already stepping up to NASH is baseball player and musician, Bernie Williams.

If you enjoy the episode, have questions or interest around its contents and Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Further, if you have questions or interest around participating in #NASHDay 2023, please let us know your ideas by writing to [email protected].

Stay Safe and Surf On!